CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
|
Total |
Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Service Receivable |
Accumulated Deficit |
Balance, beginning (in shares) at Dec. 31, 2017 |
|
60,600
|
733,217
|
|
|
|
Balance, beginning at Dec. 31, 2017 |
$ 6,506,107
|
$ 60
|
$ 5,279
|
$ 179,546,954
|
|
$ (173,046,186)
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
Stock-based compensation |
1,406,131
|
|
|
1,406,131
|
|
|
Issuance of common stock upon exercise of warrants (in shares) |
|
|
71,347
|
|
|
|
Issuance of common stock upon exercise of warrants |
1,449,167
|
|
$ 514
|
1,448,653
|
|
|
Issuance of common stock upon vesting of restricted stock units (in shares) |
|
|
12,567
|
|
|
|
Issuance of common stock upon vesting of restricted stock units |
|
|
$ 90
|
(90)
|
|
|
Preferred stock dividend payable on Series A Convertible Preferred Stock |
(6,060)
|
|
|
|
|
(6,060)
|
Net loss |
(4,786,177)
|
|
|
|
|
(4,786,177)
|
Cumulative adjustment upon adoption of ASC 606 |
109,922
|
|
|
|
|
109,922
|
Balance, ending (in shares) at Mar. 31, 2018 |
|
60,600
|
817,131
|
|
|
|
Balance, ending at Mar. 31, 2018 |
4,679,090
|
$ 60
|
$ 5,883
|
182,401,648
|
|
(177,728,501)
|
Balance, beginning (in shares) at Dec. 31, 2017 |
|
60,600
|
733,217
|
|
|
|
Balance, beginning at Dec. 31, 2017 |
6,506,107
|
$ 60
|
$ 5,279
|
179,546,954
|
|
(173,046,186)
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
Release of clinical trial funding commitment |
0
|
|
|
|
|
|
Net loss |
(8,533,132)
|
|
|
|
|
|
Balance, ending (in shares) at Jun. 30, 2018 |
|
66,250
|
2,884,168
|
|
|
|
Balance, ending at Jun. 30, 2018 |
17,477,162
|
$ 66
|
$ 7,173
|
201,720,972
|
|
(184,251,049)
|
Balance, beginning (in shares) at Mar. 31, 2018 |
|
60,600
|
817,131
|
|
|
|
Balance, beginning at Mar. 31, 2018 |
4,679,090
|
$ 60
|
$ 5,883
|
182,401,648
|
|
(177,728,501)
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
Stock-based compensation |
221,300
|
|
|
221,300
|
|
|
Issuance of common stock upon exercise of warrants (in shares) |
|
|
7,570
|
|
|
|
Issuance of common stock upon exercise of warrants |
163,500
|
|
$ 55
|
163,445
|
|
|
Preferred stock dividend payable on Series A Convertible Preferred Stock |
(6,060)
|
|
|
|
|
(6,060)
|
Issuance of common stock for share rounding as a result of reverse stock split (in shares) |
|
|
1,134
|
|
|
|
Net loss |
(3,746,955)
|
|
|
|
|
(3,746,955)
|
Sale of common stock and warrants, net of expenses (in shares) |
|
|
1,523,333
|
|
|
|
Sale of common stock and warrants, net of expenses |
11,779,525
|
|
$ 914
|
11,778,611
|
|
|
Issuance of common stock upon conversion of Series C Convertible Preferred Stock (in shares) |
|
(3,210)
|
535,000
|
|
|
|
Issuance of common stock upon conversion of Series C Convertible Preferred Stock |
|
$ (3)
|
$ 321
|
(318)
|
|
|
Sale of Series B Convertible Preferred Stock, net of expenses (in shares) |
|
8,860
|
|
|
|
|
Sale of Series B Convertible Preferred Stock, net of expenses |
4,386,762
|
$ 9
|
|
4,386,753
|
|
|
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance |
|
|
|
2,769,533
|
|
(2,769,533)
|
Balance, ending (in shares) at Jun. 30, 2018 |
|
66,250
|
2,884,168
|
|
|
|
Balance, ending at Jun. 30, 2018 |
17,477,162
|
$ 66
|
$ 7,173
|
201,720,972
|
|
(184,251,049)
|
Balance, beginning (in shares) at Dec. 31, 2018 |
|
60,600
|
3,831,879
|
|
|
|
Balance, beginning at Dec. 31, 2018 |
10,084,192
|
$ 60
|
$ 7,742
|
202,267,605
|
$ 0
|
(192,191,215)
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
Stock-based compensation |
200,067
|
|
|
200,067
|
|
|
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses of $40,000 (in shares) |
|
200,000
|
183,334
|
|
|
|
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively |
(40,000)
|
$ 200
|
$ 110
|
1,634,690
|
(1,675,000)
|
|
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance |
|
|
|
268,269
|
|
(268,269)
|
Issuance of common stock upon exercise of warrants (in shares) |
|
|
497,313
|
|
|
|
Issuance of common stock upon exercise of warrants |
3,282,266
|
|
$ 50
|
3,282,216
|
|
|
Issuance of common stock upon vesting of restricted stock units (in shares) |
|
|
6,362
|
|
|
|
Issuance of common stock upon vesting of restricted stock units |
|
|
$ 4
|
(4)
|
|
|
Preferred stock dividend payable on Series A Convertible Preferred Stock |
(6,060)
|
|
|
|
|
(6,060)
|
Issuance of common stock for share rounding as a result of reverse stock split (in shares) |
|
|
6,466
|
|
|
|
Release of clinical trial funding commitment |
70,487
|
|
|
|
70,487
|
|
Net loss |
(3,904,771)
|
|
|
|
|
(3,904,771)
|
Balance, ending (in shares) at Mar. 31, 2019 |
|
260,600
|
4,525,354
|
|
|
|
Balance, ending at Mar. 31, 2019 |
9,686,181
|
$ 260
|
$ 7,906
|
207,652,843
|
(1,604,513)
|
(196,370,315)
|
Balance, beginning (in shares) at Dec. 31, 2018 |
|
60,600
|
3,831,879
|
|
|
|
Balance, beginning at Dec. 31, 2018 |
10,084,192
|
$ 60
|
$ 7,742
|
202,267,605
|
0
|
(192,191,215)
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
Issuance of common stock upon exercise of warrants (in shares) |
|
|
497,313
|
|
|
|
Issuance of common stock for share rounding as a result of reverse stock split (in shares) |
|
|
6,466
|
|
|
|
Release of clinical trial funding commitment |
(310,766)
|
|
|
|
|
|
Net loss |
(8,030,074)
|
|
|
|
|
|
Sale of Series B Convertible Preferred Stock, net of expenses (in shares) |
|
|
1,609,511
|
|
|
|
Balance, ending (in shares) at Jun. 30, 2019 |
|
60,600
|
5,441,390
|
|
|
|
Balance, ending at Jun. 30, 2019 |
8,848,235
|
$ 60
|
$ 7,997
|
210,706,090
|
(1,364,234)
|
(200,501,678)
|
Balance, beginning (in shares) at Mar. 31, 2019 |
|
260,600
|
4,525,354
|
|
|
|
Balance, beginning at Mar. 31, 2019 |
9,686,181
|
$ 260
|
$ 7,906
|
207,652,843
|
(1,604,513)
|
(196,370,315)
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
Stock-based compensation |
148,834
|
|
|
148,834
|
|
|
Issuance of common stock upon exercise of warrants (in shares) |
|
|
156,353
|
|
|
|
Issuance of common stock upon exercise of warrants |
1,564
|
|
$ 16
|
1,548
|
|
|
Issuance of common stock upon vesting of restricted stock units (in shares) |
|
|
4,433
|
|
|
|
Issuance of common stock upon vesting of restricted stock units |
|
|
$ 0
|
0
|
|
|
Preferred stock dividend payable on Series A Convertible Preferred Stock |
(6,060)
|
|
|
|
|
(6,060)
|
Release of clinical trial funding commitment |
240,279
|
|
|
|
240,279
|
|
Net loss |
(4,125,303)
|
|
|
|
|
(4,125,303)
|
Sale of common stock and warrants, net of expenses (in shares) |
|
|
421,917
|
|
|
|
Sale of common stock and warrants, net of expenses |
2,902,740
|
|
$ 42
|
2,902,698
|
|
|
Issuance of common stock upon conversion of Series C Convertible Preferred Stock (in shares) |
|
(200,000)
|
333,333
|
|
|
|
Issuance of common stock upon conversion of Series C Convertible Preferred Stock |
|
$ (200)
|
$ 33
|
167
|
|
|
Balance, ending (in shares) at Jun. 30, 2019 |
|
60,600
|
5,441,390
|
|
|
|
Balance, ending at Jun. 30, 2019 |
$ 8,848,235
|
$ 60
|
$ 7,997
|
$ 210,706,090
|
$ (1,364,234)
|
$ (200,501,678)
|